We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Editas Medicine (EDIT) This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Editas Medicine (EDIT - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Editas Medicine is a member of the Medical sector. This group includes 983 individual stocks and currently holds a Zacks Sector Rank of #7. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Editas Medicine is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for EDIT's full-year earnings has moved 0.4% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, EDIT has gained about 98.4% so far this year. In comparison, Medical companies have returned an average of -5.4%. As we can see, Editas Medicine is performing better than its sector in the calendar year.
Another stock in the Medical sector, Adherex Technologies Inc. (FENC - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 33.1%.
The consensus estimate for Adherex Technologies Inc.'s current year EPS has increased 360% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Editas Medicine belongs to the Medical - Biomedical and Genetics industry, a group that includes 492 individual companies and currently sits at #147 in the Zacks Industry Rank. This group has gained an average of 1.5% so far this year, so EDIT is performing better in this area. Adherex Technologies Inc. is also part of the same industry.
Investors with an interest in Medical stocks should continue to track Editas Medicine and Adherex Technologies Inc.. These stocks will be looking to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging Editas Medicine (EDIT) This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Editas Medicine (EDIT - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Editas Medicine is a member of the Medical sector. This group includes 983 individual stocks and currently holds a Zacks Sector Rank of #7. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Editas Medicine is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for EDIT's full-year earnings has moved 0.4% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, EDIT has gained about 98.4% so far this year. In comparison, Medical companies have returned an average of -5.4%. As we can see, Editas Medicine is performing better than its sector in the calendar year.
Another stock in the Medical sector, Adherex Technologies Inc. (FENC - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 33.1%.
The consensus estimate for Adherex Technologies Inc.'s current year EPS has increased 360% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Editas Medicine belongs to the Medical - Biomedical and Genetics industry, a group that includes 492 individual companies and currently sits at #147 in the Zacks Industry Rank. This group has gained an average of 1.5% so far this year, so EDIT is performing better in this area. Adherex Technologies Inc. is also part of the same industry.
Investors with an interest in Medical stocks should continue to track Editas Medicine and Adherex Technologies Inc.. These stocks will be looking to continue their solid performance.